Boston Scientific has reported positive clinical data from a trial, demonstrating the long-term safety of bronchial thermoplasty in patients treated with the company’s Alair bronchial thermoplasty system.
Developed by Asthmatx, the Alair system delivers thermal energy to the airway wall in a precise and controlled manner to reduce excessive airway smooth muscle, thereby reducing the frequency and severity of asthma attacks.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial, known as RISA, demonstrated that stable lung function is maintained and late clinical complications are absent over a five-year period in patients with severe refractory asthma treated with bronchial thermoplasty.
The data is consistent with recently published five-year data from the seperate AIR trial, which also demonstrated a long-term safety profile for the Alair System.
RISA trial principal investigator Dr Laviolette said that bronchial thermoplasty provides a new option for treating patients with severe asthma, and can provide proven reductions in hospital costs and visits.
"Existing evidence suggests a significant long-term benefit, and results from the RISA trial clearly confirm long-term safety,” Laviolette added.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
